Cardio3biosciences
MONT-SAINT-GUIBERT, Belgium, September 22, 2011 -
The Belgian biotechnology company, Cardio3 BioSciences, a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiovascular diseases, announced today that it has established a subsidiary, Cardio3 BioSciences, Inc.
MONT-SAINT-GUIBERT, Belgium, April 5, 2011 - The Belgian biotechnology company, Cardio3 BioSciences, a
leader in discovery and development of regenerative and protective therapies
for the treatment of cardiovascular diseases, today presented detailed data
from the Phase II clinical trial of C3BS-CQR-1 (C-Cure(R)), its novel stem
cell therapy for ischemic cardiomyopathy, at the 60th annual American College
of Cardiology in New Orleans, USA.
MONT-SAINT-GUIBERT, Belgium, December 20, 2010 - The Belgian biotechnology company, Cardio3 BioSciences, a leader in the
discovery and development of regenerative and protective therapies for the
treatment of cardiovascular diseases, today announces positive pre-clinical
results from its in-house product candidate C3BS-GQR-1, a "cardiopoietic"
cocktail designed to treat patients suffering from acute myocardial
infarction in order to protect cardiac tissue from damage and direct heart
stem cells to mature and restore pump function.
